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Abstract
Background: Failure of adipocytes to expand during periods of energy excess can result in undesirable metabolic
consequences such as ectopic fat accumulation and insulin resistance. Blinded screening studies have indicated that
Artemisia scoparia (SCO) extracts can enhance adipocyte differentiation and lipid accumulation in cultured adipocytes. The
present study tested the hypothesis that SCO treatment modulates fat cell development and function in vitro and insulin
sensitivity in adipose tissue in vivo.
Methods: In vitro experiments utilized a Gal4-PPARc ligand binding domain (LBD) fusion protein-luciferase reporter assay to
examine PPARc activation. To investigate the ability of SCO to modulate adipogenesis and mature fat cell function in 3T3-L1
cells, neutral lipid accumulation, gene expression, and protein secretion were measured by Oil Red O staining, qRT-PCR, and
immunoblotting, respectively. For the in vivo experiments, diet-induced obese (DIO) C57BL/6J mice were fed a high-fat diet
(HFD) or HFD containing 1% w/w SCO for four weeks. Body weight and composition, food intake, and fasting glucose and
insulin levels were measured. Phospho-activation and expression of insulin-sensitizing proteins in epididymal adipose tissue
(eWAT) were measured by immunoblotting.
Results: Ethanolic extracts of A. scoparia significantly activated the PPARc LBD and enhanced lipid accumulation in
differentiating 3T3-L1 cells. SCO increased the transcription of several PPARc target genes in differentiating 3T3-L1 cells and
rescued the negative effects of tumor necrosis factor a on production and secretion of adiponectin and monocyte
chemoattractant protein-1 in fully differentiated fat cells. DIO mice treated with SCO had elevated adiponectin levels and
increased phosphorylation of AMPKa in eWAT when compared to control mice. In SCO-treated mice, these changes were
also associated with decreased fasting insulin and glucose levels.
Conclusion: SCO has metabolically beneficial effects on adipocytes in vitro and adipose tissue in vivo, highlighting its
potential as a metabolically favorable botanical supplement.
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Introduction
Adipocytes have long been recognized as storage sites for excess
energy. A growing body of evidence has demonstrated that
adipose tissue can also act as an endocrine organ and functions as
an important regulator of whole-body energy homeostasis. The
endocrine actions of adipocytes can regulate physiological
processes, including whole-body insulin sensitivity, glucose uptake,
and feeding behavior [1,2]. Obesity is the primary disease of
adipocytes and is a risk factor for the development of type 2
diabetes mellitus (T2DM), cardiovascular disease, and certain
cancers. During periods of energy excess, obesity can result from
either adipocyte hypertrophy (increased cell size) or adipocyte
hyperplasia (increased cell number) or a combination of the two.
Since mature fat cells do not proliferate, adipogenesis accompanies
hyperplasia of progenitor cells [3]. In recent years, the inhibition of
PLOS ONE | www.plosone.org 1 June 2014 | Volume 9 | Issue 6 | e98897
adipogenesis was thought to be an attractive therapeutic modality
for the attenuation or prevention of obesity. However, evidence
has since emerged demonstrating that disruption of adipocyte
differentiation and/or expansion is maladaptive and leads to
ectopic fat accumulation and metabolic dysfunction, including
insulin resistance and T2DM [4,5]. Furthermore, increased
adipocyte turnover due to an elevated rate of cell death can be
associated with obesity [6]. These findings favor an alternative
hypothesis that adipose tissue expansion associated with increased
adipogenesis results in adipocytes with beneficial endocrine
functions that contribute to an improved metabolic status during
obesity.
Plant-derived nutritional supplements have long been used by
many cultures to promote health and resilience and to prevent or
treat disease. Plant extracts have also been used in the
development of many drugs, including metformin, a widely used
T2DM drug derived from French lilac. In an effort to identify
botanical modulators of fat cell development and function, we
screened a large variety of botanical extracts. Results from this
blinded screening effort led to the identification of an ethanolic
extract of Artemisia scoparia (SCO) that enhanced adipocyte
differentiation and lipid accumulation. Several Artemisia species
have been used in traditional medicine in East Asia, and have been
shown to lower blood glucose [7,8], combat obesity [9,10], and
prevent T2DM [8,11] in rodent models of obesity and metabolic
dysfunction.
Since our initial findings indicated that SCO promotes
adipogenesis, we then examined the ability of SCO to modulate
fat cell development and function in vitro and insulin sensitivity in
adipose tissue in vivo. Our novel results demonstrate that SCO
activates the ligand binding domain (LBD) of peroxisome
proliferator activated receptor gamma (PPARc), a critical tran-
scriptional regulator of fat cell differentiation [12]. Our results also
indicate that SCO increases the transcription of several PPARc
target genes in differentiating 3T3-L1 cells and rescues the
negative effects of tumor necrosis factor a (TNFa) on adipocyte
secretion of adiponectin (ADPN) and monocyte chemoattractant
protein-1 (MCP-1). In diet-induced obese (DIO) mice fed a high
fat diet (HFD) or a HFD containing SCO for 4 weeks, SCO
increased the activation and expression of insulin-sensitizing
proteins in adipose tissue. These changes were associated with
decreased fasting serum insulin and glucose levels in SCO-treated
mice. Overall, the data demonstrate that SCO has metabolically
beneficial effects on adipocytes in vitro and adipose tissue in vivo,
and indicate its potential as a metabolically favorable botanical
supplement.
Materials and Methods
Preparation, source, and characterization of the extracts
Artemisia scoparia Waldst. & Kit ethanolic extracts were prepared
at Rutgers University. Briefly, the herb was greenhouse-grown
from seed and periodically harvested at the flowering stage, then
freeze-dried and stored at220uC. The dried herb was extracted in
80% ethanol (1:20 w/v) at 50uC with sonication for 1 hour
followed by shaking at room temperature for 24 h. The solid
material was removed by centrifugation at 3000 g and the solvent
was subsequently removed by evaporation. For in vitro and cell
culture experiments, the dried extracts were solubilized in 100%
dimethyl sulfoxide (DMSO) at a concentration that was 1000-fold
higher than experimental concentrations and then diluted into the
media. For animal studies, the extracts were mixed with the HFD,
and the resulting mixture was pelleted.
PPARc LBD activation assay
Botanical extracts were assessed for their ability to modulate the
activity of the PPARc LBD using a previously described Gal4
DNA binding domain-PPARc LBD fusion protein co-transfection
assay system [13–15]. All extracts were tested at 50 mg/ml and
rosiglitazone (Rosi) was used as a positive control. DMSO was
used as a vehicle control.
Cell culture
Murine 3T3-L1 preadipocytes, purchased directly from Dr.
Green’s laboratory [16], were plated and grown to 2 days post-
confluence in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% bovine serum. Medium was changed every 48–
72 hours. Cells were induced to differentiate using a standard
MDI induction protocol [17]. Mature adipocytes were maintained
in DMEM supplemented with 10% FBS until utilized for
experimentation. DMEM was purchased from Sigma-Aldrich
(St. Louis, MO). Bovine and fetal bovine sera were purchased from
HyClone (Thermo Scientific, Logan, UT). For adipogenesis
assays, the botanical extracts were added at the time of MDI
induction and at each media change until the cells were stained
with Oil Red O (ORO) or harvested for gene expression analysis.
Fully differentiated adipocytes were used for the TNFa experi-
ments. To initiate treatment (day 0), the media was changed to
DMEM supplemented with 5% calf serum. The cells were
maintained in this media for the duration of the experiment with
fresh media added on day 2. Beginning on day 0, the mature
adipocytes were treated with 25 mg/mL SCO, 1 mM rosiglitazone
(Rosi), or DMSO vehicle daily. TNFa (1 nM) was also added as
indicated on days 1 and 3. On day 4, 1 mL of conditioned media
was collected from each well and mixed with 1mM phenylmethyl-
sulfonyl fluoride (PMSF). The remaining media was aspirated, and
then cell monolayers were collected for gene expression analysis.
Oil Red O staining
An ORO stock was prepared as previously described [18]. Cell
monolayers were aspirated, rinsed with PBS, fixed in 10%
formaldehyde in PBS, and rinsed under tap water. The remaining
water was aspirated, and the cells were incubated for 1 h in the
working ORO solution (0.3% in isopropanol). Following incuba-
tion, stain aspiration, and rinsing, cells were examined by
microscopy and scanned to produce the figures in this manuscript.
Animals and diets
Twenty 16-week old male C57BL/6J-60% DIO mice were
purchased from Jackson Laboratories (Bar Harbor, ME). Upon
arrival to PBRC, mice were housed two per cage and placed into
quarantine for one week. After quarantine, mice were randomized
by body weight into 2 groups: HFD or HFD + SCO, and then
singly housed under constant temperature and humidity (2162uC
with humidity 65–75%) and a 12:12 h light-dark cycle. Mice had
ad libitum access to assigned diets and water for the duration of the
experimental period. Mice had access to HFD containing
20 kcal% protein, 20 kcal% carbohydrate, and 60 kcal% fat
(D12492; Research Diets, Inc., New Brunswick, NJ) or HFD +1%
w/w SCO. Food intake was measured weekly for the duration of
the experiment. All animal studies were performed with approval
from the Pennington Biomedical Research Center Institutional
Animal Care and Use Committee (Permit #665P).
Animal Study Procedures
On day 0 and days 7, 14, 21, and 28 of the experimental
period, mice were weighed and non-fasting body composition was
Artemisia Induces Metabolically Favorable Effects in Fat
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measured by NMR (Bruckner Minispec). Submandibular blood
collection was performed on each mouse following a 4-hour fast at
the beginning (day 0; baseline measurements) and end of the 4-
week study period (day 27) to assess fasting levels of serum glucose
and insulin. Fasting glucose levels were measured using a YSI
glucose analyzer (YSI Life Sciences, Yellow Springs, OH). Fasting
insulin levels were determined by a Crystal Chem rat/mouse
insulin enzyme-linked immunosorbent (ELISA) kit (Crystal Chem,
Downers Grove, IL). Mice were overnight fasted on day 28 and
sacrificed on day 29. Ten minutes prior to sacrifice, animals were
injected with saline or 1 U/kg insulin (Humulin R, Eli Lilly,
Indianapolis, IN) and then euthanized via cervical dislocation and
decapitation. The epididymal white adipose tissue depot (eWAT)
was collected and immediately frozen in liquid nitrogen.
Determination of homeostasis model assessment of
insulin resistance
The homeostasis model assessment of insulin resistance
(HOMA-IR) was calculated using glucose and insulin concen-
trations obtained after a 4-hour fast, using the following formula:
fasting glucose (mg/dl) 6 fasting insulin (mU/ml)/405 [19,20].
Gene expression analysis
Total RNA was isolated from cell monolayers with the RNeasy
mini kit (Qiagen). RNA concentrations were measured using a
NanoDrop ND-1000 UV-Vis Spectrophotometer. Reverse tran-
scription (RT) was performed using 400–500 ng of RNA and the
RT2 First Strand Kit (Qiagen). An Applied Biosystems 7900HT
thermocycler system was used to conduct all real-time qRT-PCR
analyses. For gene expression analysis of the adipogenesis assay,
cDNA was quantified using a custom RT2 Profiler PCR Array and
the RT2 SYBR Green qPCR Mastermix (Qiagen). The wet-bench
validated mouse RT2 Primer Assays used in the custom 12632 (12
genes by 32 samples) array included: adiponectin (PPM05260),
fatty acid binding protein 4 (FABP4; PPM04517), fatty acid
synthase (FASN; PPM03816), PPARc (PPM05108), CCAAT/
enhancer binding protein (C/EBP), alpha (CEBPa; PPM04674),
CEBPb (PPM03505), CEBPd (PPM04676), Sterol regulatory
element binding transcription factor 1 (SREBF1; PPM05094),
Solute carrier family 2 (facilitated glucose transporter), member 4
(GLUT4; PPM04166), Glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH; PPM02946), and Peptidyl prolyl isomerase H
(PPIH; PPM03699). GAPDH and PPIH were included as
housekeeping genes, and all data were normalized against PPIH
as the endogenous control. Data were analyzed using the DDCT
method via the PCR Array Data Analysis Web Portal (http://
www.sabiosciences.com/pcrarraydataanalysis.php). For the gene
expression analysis of the TNFa experiments in mature adipo-
cytes, cDNA was quantified using the SYBR supermix reagent
(Takara) and the following primers: mAdiponectin forward
AAAAGGGCTCAGGATGCTACTG reverse TGGGCAG-




TGGGGCGTTAACTGCATCTGG; mCyclophilin A forward
CCACTGTCGCTTTTCGCCGC reverse TGCAAACAGCTC-
GAAGGAGACGC. Standard curves were used to generate
relative expression data, and mCyclophilin A was used as the
endogenous control.
Whole cell extract and tissue preparation for protein
analysis
Adipocyte whole cell extracts and eWAT lysates were prepared
by either harvesting adipocyte monolayers or homogenizing
eWAT in a non-denaturing extraction buffer containing 10 mM
Tris, pH 7.4, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1%
Triton X-100, 0.5% Igepal CA-630, 1 mM PMSF, 1 mM
pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10 mM
leupeptin, 1 mM 1, 10-phenanthroline, and 0.2 mM sodium
vanadate. For cultured adipocytes, monolayers were scraped into
the lysis buffer, subjected to one freeze-thaw cycle, and passed
3 times through a 20-gauge needle. The lysates or homogenates
were then centrifuged at 17,500 g for 10 minutes at 4uC. After
removing the floating lipid layer, the protein concentrations of the
supernatants were determined by a BCA kit (Thermo Scientific,
Rockford, IL) according to the manufacturer’s instructions.
Gel electrophoresis and immunoblotting
Reduced and heat-denatured samples were separated on 10%
SDS-polyacrylamide gels (acrylamide from National Diagnostics).
For native gel electrophoresis, 5% polyacrylamide gels were
prepared without SDS. Additionally, SDS and reducing agents
were eliminated from the running and sample loading buffers.
Following gel electrophoresis, proteins were transferred to
nitrocellulose membranes in transfer buffer containing 25 mM
Tris, 192 mM glycine, and 20% methanol. Traditional immuno-
blotting procedures were followed, and results were visualized with
horseradish peroxidase-conjugated secondary antibodies and
enhanced chemiluminescence (Thermo Scientific, Rockford, IL).
Primary antibodies included: the anti-adiponectin antibody from
Thermo Scientific (Rockford, IL); phospho-AMPKa (Thr172),
phospho-Akt (Ser473), and MCP-1 antibodies purchased from
Cell Signaling Technology, Inc. (Danvers, MA); and anti-MAPK
(Erk 1/2) antibody from Santa Cruz Biotechnology, Inc. (Dallas,
TX). Anti-rabbit and anti-mouse IgG secondary antibodies were
purchased from Jackson ImmunoResearch (West Grove, PA).
Optical densities of all protein bands were analyzed using Image
Studio Lite software (Licor Biosciences, Lincoln, NE).
Statistical analyses
Gene expression data for ADPN, MCP-1, and IL-6 and optical
density data for phospho-AMPKa (Thr172), phospho-Akt
(Ser473), and ADPN were analyzed by independent, two-tailed
t-tests using GraphPad Prism version 6 (La Jolla, CA). Linear
models were obtained using SAS 9.3.
Results
We screened over 400 botanical extracts for their ability to
activate PPARc and modulate adipogenesis in 3T3-L1 cells. As
shown in Figure 1A, extracts prepared from A. scoparia significantly
activated the PPARc LBD 5–6 fold relative to the untreated
control. The well-known synthetic PPARc agonist and insulin
sensitizer, rosiglitazone, was examined as positive control.
Rosiglitazone stimulated the PPARc LBD and increased the
luciferase reporter activity by 13-fold over the control values.
Multiple SCO extracts (00476) were examined and included
preparations from the entire plant (E13), above ground organs
(E12), leaves (E7), stem (E4), and root (E1). Only the extracts
prepared from the entire plant, above ground organs, and the
leaves were capable of significantly activating PPARc. ORO
staining was used to assess the ability of botanical extracts to
increase neutral lipid accumulation during fat cell differentiation
and served as an indicator of their ability to promote adipogenesis.
Artemisia Induces Metabolically Favorable Effects in Fat
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Compared to the untreated and vehicle (DMSO) treated wells, the
A. scoparia extracts prepared from the leaves, above ground organs,
and the entire plant increased ORO staining during the
adipogenesis of 3T3-L1 cells (Figure 1B). These data demonstrate
that the SCO extracts that were capable of substantially activating
the PPARc LBD were also adipogenic. As shown in Figure 1, Aster
dumosus L. (Garden Aster) was also capable of stimulating the
PPARc LBD and promoting adipogenesis. However, in these
studies we focused on investigating the effects of an A. scoparia
extract prepared from the above ground organs (SCO) on
adipocyte development and function in 3T3-L1 cells and DIO
mice.
To further investigate the ability of SCO to promote
adipogenesis, 3T3-L1 preadipocytes were induced to differentiate
in the presence of different doses of SCO or DMSO vehicle. The
cells were harvested on day 5 after initiating differentiation to
examine gene expression. This analysis revealed that SCO
substantially upregulated the expression of adipogenic transcrip-
tion factors, C/EBPs a and b. Moreover, SCO significantly
induced expression of PPARc and several of its target genes in a
dose-dependent manner (Figure 2).
After inspecting the data, there appeared to be a linear
relationship between SCO dose and gene expression. By treating
dose as a continuous measurement, a linear model was used to
estimate the effect of dose on gene expression. A strong linear
relationship (p,0.01) was shown in PPARc, GLUT4, and FASN.
A linear relationship (p,0.05) was also shown in FABP4, ADPN,
and CEBPs b and d.
TNFa is a pro-inflammatory cytokine that has been implicated
in insulin resistance and has been shown to inhibit ADPN
production [21–23]. MCP-1 is a cytokine that recruits monocytes
to sites of inflammation and has been shown to contribute to
pathologies associated with metabolic syndrome [24]. We used
immunoblot analysis to evaluate the effect of SCO on ADPN and
MCP-1 secretion from cultured, fully differentiated murine
adipocytes that were also exposed to TNFa (Figure 3A). Our
results demonstrated that TNFa decreased ADPN secretion and
increased MCP-1 secretion from mature adipocytes. These TNFa-
Figure 1. Ethanolic extracts of A. scoparia activate the PPARc LBD and promote adipogenesis in vitro. A) HEK293 cells were co-transfected
with a Gal4 DNA binding domain – PPARc LBD fusion protein and a luciferase reporter construct. In a blinded screen, botanical extracts were tested at
50 mg/ml. Untreated (control) and rosiglitazone-treated cells were used as negative and positive controls, respectively. All of the extracts shown were
prepared from plants collected in Kyrgyzstan. Assay results are shown for A. scoparia Walst. & Kit (00476E1– root, E12– above ground portion of plant,
E13– entire plant, E4– stem, and E7– leaf), Artemisia aschurbajewii C.Winkl. (00550E13), Artemisia macrocephala Jacquem. ex Besser (00543E12– above
ground, E13 entire plant), Artemisia vulgaris L. (00508E13), Aster altaicus Willd. (00202E12), Aster vvedenskyi Bondarenko (00605E13), Aster dumosus L.
(00736E13), and Crataegus submollis Sarg. (00749E12). Data are presented as mean 6 SEM (n= 3); * denotes p,0.05. B) Murine 3T3-L1 preadipocytes
were induced to differentiate using the typical MDI induction cocktail containing 50 mg/ml of the indicated extracts. Cell monolayers were subjected
to Oil Red O staining 96 hours after the induction of adipogenesis.
doi:10.1371/journal.pone.0098897.g001
Figure 2. SCO increases the expression of PPARc target genes
associated with adipogenesis in a dose-dependent manner in
3T3-L1 cells. Differentiation of murine 3T3-L1 preadipocytes was
induced using the standard MDI induction cocktail containing 25 mg/ml
(SCO-25) or 50 mg/ml (SCO-50) of SCO or DMSO vehicle. Cell
monolayers were collected on day 5 following administration of the
MDI cocktail. RNA was isolated, purified, and subjected to qRT-PCR.
Data are presented as mean 6 SEM (n= 3) for each gene; * denotes
significant difference compared to vehicle (p,0.05), ** (p,0.01).
doi:10.1371/journal.pone.0098897.g002
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induced changes in adipokine secretion were attenuated by SCO
treatment (Figure 3A). Analysis of mRNA isolated from the same
adipocytes used for the experiments shown in Figure 3A revealed
that SCO treatment restored the TNFa-induced downregulation
of ADPN expression, and attenuated the TNFa-induced upregu-
lation of MCP-1 and IL-6, another pro-inflammatory cytokine
(Figure 3B). Rosiglitazone was used as a positive control in these
experiments (Figures 3A and 3B).
For our in vivo experiments, we fed mice HFD or HFD + SCO
for 4 weeks and assessed the effect of SCO on serum insulin and
glucose (Figure 4A). The SCO-treated mice had significantly lower
serum insulin concentrations compared to controls (p,0.02).
Analysis of serum glucose revealed that the treated mice had lower
glucose levels than controls but the difference did not reach
statistical significance (p = 0.0551). However, insulin resistance in
the SCO-treated mice was significantly lower compared to
controls, as determined by HOMA-IR quantitative assessment
(Figure 4B). Results for body weight, body composition, and food
intake did not differ between the two groups at the end of the 4-
week study period (Table 1).
AMP-activated protein kinase (AMPK) is an enzyme that plays
a critical role in energy homeostasis in a variety of cells and is
activated by adiponectin [25,26]. Akt plays a central role in several
critical cellular responses and is integral to insulin signaling [27].
We assessed the ability of SCO to modulate these proteins in
eWAT collected from control or SCO-treated mice. As shown in
Figure 5, immunoblot analysis revealed that phosphorylation of
AMPK (pT172) was increased in SCO-treated mice as compared
to the untreated controls, but this difference did not reach
statistical significance (p = 0.068). We also observed a trend toward
increased ADPN levels in the eWAT of treated mice compared to
controls (p = 0.083), while SCO-treatment did not substantially
modulate phosphorylation of Akt (pS473).
Discussion
The search for effective preventive or therapeutic interventions
to combat obesity and T2DM is critical. There is a time-honored
tradition of using botanical products in complementary medicine.
However, few studies examine biological mechanisms that mediate
botanical activity. In our laboratory, results from blinded screening
studies examining the effects of botanicals on adipocyte differen-
tiation suggested that A. scoparia extracts warranted further
investigation. In the present study, we examined the effects of A.
scoparia on several factors involved in adipocyte development and
insulin signaling. The results of our experiments support the
hypothesis that A. scoparia modulates biological factors relevant to
obesity and T2DM and promotes the development of an
advantageous metabolic phenotype.
We examined the effects of several A. scoparia extracts on PPARc
LBD activation and adipocyte development in murine 3T3-L1
cells. Our results demonstrated that extracts prepared from the
entire plant, above ground organs, and leaves significantly
activated the PPARc LBD and promoted adipogenesis as judged
by lipid accumulation. These data indicate that the pro-adipogenic
bioactive components reside in the leaves and possibly flowers (not
individually tested), but are not present in the stems or roots of A.
scoparia.
PPARc is a transcription factor that functions a master
transcriptional regulator of adipogenesis [28]. Thiazolidinediones
(TZDs), a class of anti-diabetic drugs that are potent activators of
PPARc, also modulate adipocyte development and function. The
potent insulin-sensitizing activities of TZDs have been effective in
diminishing the progression from impaired glucose tolerance to
T2DM [29,30]. However, undesirable side effects have led to
recent decreases in the use of TZDs as therapeutics [31–33].
Future studies will be performed to assess whether SCO has any of
the undesirable effects of TZDs. Currently, non-traditional
Figure 3. SCO attenuates TNFa-induced effects on adipokine
secretion in 3T3-L1 adipocytes. Fully differentiated 3T3-L1 adipo-
cytes were treated for 4 days (treatment began on day 0) in triplicate
on six-well plates. Cells were treated with 25 mg/mL SCO, 1 mM
rosiglitazone (Rosi), or DMSO vehicle daily. TNFa (1 nM) was also added
as indicated on days 1 and 3. On day 4, conditioned media and cell
monolayers were collected, respectively, for protein and gene
expression analysis. A) Conditioned media samples (250 mg total
protein/sample) were separated using SDS-PAGE, transferred to
nitrocellulose, and subjected to immunoblot analysis. B) Purified RNA
was subjected to qRT-PCR analysis to examine gene expression. Data
are presented as mean 6 SEM (n= 3). For each gene, * denotes
significant difference compared to TNF (p,0.05), ** (p,0.01).
doi:10.1371/journal.pone.0098897.g003
Figure 4. SCO decreases insulin and glucose levels in vivo. DIO
C57BL/6J mice were fed a HFD or HFD + SCO for 4 weeks. A) Following
a 4-hour fast, serum insulin and glucose levels were measured. *
denotes significant difference relative to HFD control (p,0.02). B)
HOMA-IR was calculated from fasting insulin and glucose levels. **
denotes p,0.01. Data are presented as mean 6 SEM (n= 9–10).
doi:10.1371/journal.pone.0098897.g004
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PPARc activators that may have anti-diabetic activity are being
developed [34,35]. We predict that botanicals, like SCO, may be a
natural source of PPARc activators that are less potent, but retain
anti-diabetic actions.
Our studies demonstrate that SCO increases PPARc’s tran-
scriptional activity, as indicated by its ability to activate the LBD of
PPARc (Figure 1A) and by its induction of several PPARc target
genes (Figure 2). Notably, SCO increased the gene expression of
ADPN, FABP4, FASN, and GLUT4, which are all PPARc target
genes, in a clearly dose-dependent pattern. While SCO obviously
activates PPARc, further experiments are needed to determine
whether these effects are direct or indirect. SCO may contain a
bioactive component that is a direct ligand of PPARc, but also it is
equally possible that SCO-treatment activates PPARc indirectly in
cultured cells by increasing the production of PPARc ligands or
modulating post-translational modifications that control PPARc
activity. Overall, these results provide evidence that SCO
promotes adipocyte development in vitro and warrant closer
investigation of its possible effects in promoting a favorable
metabolic status.
Chronic inflammation is a hallmark of obesity and insulin
resistance and is highly associated with macrophage infiltration
into adipose tissue [36]. TNFa, a pro-inflammatory cytokine that
plays a role in adipose tissue inflammation, inhibits the production
of adiponectin, an adipocyte-derived hormone that can increase
insulin sensitivity and glucose uptake [26,37]. MCP-1 also is
involved in the inflammatory response. Our results demonstrated
that SCO attenuated the TNFa-induced increase in MCP-1
secretion and partially reversed the inhibition of adiponectin
secretion in response to TNFa treatment, but these effects were
not as robust as those seen with rosiglitazone (Figure 3A). The
ability of SCO to attenuate the negative effects of TNFa on
adipokine secretion was associated with similar responses on the
gene expression level (Figure 3B), suggesting that the ability of
SCO to modulate adipokine secretion in the presence of TNFa is
dependent on transcriptional responses. SCO also blunted the
TNFa-mediated increase in IL-6, which is another pro-inflamma-
tory cytokine that has been shown to induce insulin resistance in
adipocytes [38,39]. These results provide evidence that SCO
favorably modulates the secretory function of fat cells by
attenuating the production of inflammatory markers (MCP-1
and IL-6) in adipocytes and rescuing the production of ADPN.
Thus, SCO may have potential as a therapeutic in metabolic
syndrome, which is strongly associated with chronic low grade
inflammation and insulin resistance.
Our in vivo experiments demonstrated that treatment of DIO
mice with SCO resulted in significantly lower fasting serum insulin
levels when compared to controls. We also observed a reduction in
fasting serum glucose that did not reach statistical significance
(Figure 4A). Moreover, our finding that the HOMA-IR of the
SCO-treated mice was significantly lower compared to controls
(Figure 4B) is an indicator that SCO attenuated insulin resistance
in these animals. We also have data showing that SCO enhanced
insulin-stimulated glucose disposal during insulin tolerance tests in
mice that had been administered SCO or vehicle via gavage for
one week (data not shown). Taken together, these results suggest
that SCO enhances insulin action in mice.
Further analysis of our in vivo experiment demonstrated that
SCO enhanced the activation and expression of insulin-sensitizing
proteins in eWAT. The phosphorylation of AMPK was increased
in SCO-treated mice. AMPK is a potent integrator of cellular
energy status and is activated when the ATP to AMP ratio is low.
Table 1. Food intake, body weight, and body composition in mice at end of study.
Body Composition
Group Food intake/day Body weight FM FFM Fluid
(g)
HFD 2.8560.31 47.6261.02 15.9161.00 25.1260.48 4.8460.15
HFD + SCO 3.0660.28 45.9961.08 15.7161.11 24.4460.42 4.8660.09
doi:10.1371/journal.pone.0098897.t001
Figure 5. SCO enhances adiponectin expression and AMPK
activation in adipose tissue. DIO C57BL/6J mice were fed HFD or
HFD + SCO for 4 weeks. Ten minutes prior to sacrifice, mice were
injected with insulin. Protein homogenates prepared from eWAT were
separated by SDS-PAGE and analyzed by immunoblot analysis.
Representative immunoblots for AMPK and Akt (A) and adiponectin
(B) are shown. C) Band intensities were quantified using Image Studio
Lite software and normalized against the respective MAPK optical
densities. Fold change relative to HFD alone for each protein was
calculated, and mean 6 SEM (n = 4–5) is graphed.
doi:10.1371/journal.pone.0098897.g005
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In addition to regulating energy homeostasis, AMPK regulates
several cellular processes, including mitochondrial function and
biogenesis, inflammation, oxidative and ER stress, and autophagy
[25]. Recent findings indicate that AMPK plays a role in adipose
tissue by regulating lipid and carbohydrate metabolism, adipo-
genesis, and inflammatory pathways [40]. In addition to measur-
ing AMPK phosphorylation, we also examined phosphorylation of
Akt, a critical insulin signaling enzyme that also modulates several
other key cellular processes, such as apoptosis, proliferation, and
cell migration [27].
The finding that SCO treatment enhances AMPK phosphor-
ylation in mouse eWAT provides further evidence that this
botanical could promote metabolically favorable adaptations. In
rodent muscle, activated AMPK has been shown to directly
phosphorylate the insulin receptor, resulting in non-insulin-
dependent stimulation of the insulin signaling pathway [41].
Increased AMPK phosphorylation is associated with improved
insulin sensitivity and decreased IRS-1 serine phosphorylation,
which improves insulin action [42]. However, we did not observe
improved insulin signaling in the eWAT of SCO-treated mice
relative to the controls, as determined by examining insulin-
responsive Akt serine phosphorylation in the eWAT homogenates.
Since AMPK also modulates adipose tissue lipid metabolism [43],
it is possible that increased AMPK phospho-activation in eWAT
results in less lipid release and increased lipid oxidation in fat tissue
that could be associated with less ectopic fat accumulation in liver
and muscle and enhanced insulin sensitivity and glucose regulation
in the whole animal. Further studies examining plasma triglyceride
levels and ectopic lipid accumulation in muscle and liver are
needed to test this hypothesis.
Although the present study did not assess the effect of SCO on
insulin action in liver and skeletal muscle, there is experimental
evidence to show that SCO and other related Artemisia species
increase insulin-stimulated Akt phosphorylation in both of these
tissues [44–47]. We cannot exclude the possibility that treatment
with SCO affected insulin signaling in the liver and skeletal muscle
of the treated animals in this study and therefore could partially
account for the observed decrease in insulin and glucose.
Conclusions
The findings from our in vitro and in vivo studies on the effects of
SCO on adipocyte development and function and insulin action
indicate its potential as a therapeutic capable of promoting
metabolically advantageous changes in the context of obesity/
T2DM. The potency of SCO as a PPARc agonist indicates that
further investigation is necessary to determine its efficacy as a
complementary therapy in the prevention and/or treatment of
T2DM; SCO may have some of the insulin-sensitizing benefits of
TZDs without the unfavorable side effects. SCO has positive
effects on several biological markers of insulin resistance,
inflammation, and adipocyte function. The attenuation of pro-
inflammatory proteins, MCP-1 and IL-6, along with the stimu-
lation of adiponectin expression in adipocytes and adipose tissue,
demonstrates the viability of SCO as an agent that promotes the
maintenance of metabolic health. Results from our studies suggest
that A. scoparia should be further studied in the search to find
metabolically beneficial therapeutics for obesity and T2DM and to
understand the mechanism(s) by which botanicals can improve
metabolic dysfunction.
Acknowledgments
We would like to thank Anik Boudreau for technical assistance, Cody
Martin for help with cell culture experiments and immunoblotting
analyses, Tamara Mendoza for assistance with the animal study, and Dr.
William Johnson for help with statistical analyses. We also extend our
gratitude to Dr. Carrie Elks for critical reading and editing of the
manuscript.
Author Contributions
Conceived and designed the experiments: JMS AJR RM. Performed the
experiments: AJR VF TPB. Analyzed the data: AJR TPB RB. Contributed
reagents/materials/analysis tools: DMR. Wrote the paper: AJR SF JMS.
References
1. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE (2001) The adipocyte-
secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7: 947–953.
10.1038/90992 [doi];90992 [pii].
2. Mantzoros CS (1999) The role of leptin in human obesity and disease: a review
of current evidence. Ann Intern Med 130: 671–680. 199904200-00008 [pii].
3. Sun K, Kusminski CM, Scherer PE (2011) Adipose tissue remodeling and
obesity. J Clin Invest 121: 2094–2101. 45887 [pii];10.1172/JCI45887 [doi].
4. Danforth E Jr (2000) Failure of adipocyte differentiation causes type II diabetes
mellitus? Nat Genet 26: 13. 10.1038/79111 [doi].
5. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, et al. (2007)
Obesity-associated improvements in metabolic profile through expansion of
adipose tissue. J Clin Invest 117: 2621–2637. 10.1172/JCI31021 [doi].
6. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, et al. (2005) Adipocyte
death defines macrophage localization and function in adipose tissue of obese
mice and humans. J Lipid Res 46: 2347–2355. M500294-JLR200 [pii];10.1194/
jlr.M500294-JLR200 [doi].
7. Ribnicky DM, Poulev A, Watford M, Cefalu WT, Raskin I (2006)
Antihyperglycemic activity of Tarralin, an ethanolic extract of Artemisia
dracunculus L. Phytomedicine 13: 550–557. S0944-7113(05)00210-2
[pii];10.1016/j.phymed.2005.09.007 [doi].
8. Xing XH, Zhang ZM, Hu XZ, Wu RQ, Xu C (2009) Antidiabetic effects of
Artemisia sphaerocephala Krasch. gum, a novel food additive in China, on
streptozotocin-induced type 2 diabetic rats. J Ethnopharmacol 125: 410–416.
S0378-8741(09)00453-X [pii];10.1016/j.jep.2009.07.021 [doi].
9. Lim DW, Kim YT, Jang YJ, Kim YE, Han D (2013) Anti-obesity effect of
Artemisia capillaris extracts in high-fat diet-induced obese rats. Molecules 18:
9241–9252. molecules18089241 [pii];10.3390/molecules18089241 [doi].
10. Yamamoto N, Kanemoto Y, Ueda M, Kawasaki K, Fukuda I, et al. (2011) Anti-
obesity and anti-diabetic effects of ethanol extract of Artemisia princeps in
C57BL/6 mice fed a high-fat diet. Food Funct 2: 45–52. 10.1039/c0fo00129e
[doi].
11. Hamza N, Berke B, Cheze C, Agli AN, Robinson P, et al. (2010) Prevention of
type 2 diabetes induced by high fat diet in the C57BL/6J mouse by two
medicinal plants used in traditional treatment of diabetes in the east of Algeria.
J Ethnopharmacol 128: 513–518. S0378-8741(10)00020-6 [pii];10.1016/
j.jep.2010.01.004 [doi].
12. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM (2000) Transcriptional
regulation of adipogenesis. Genes Dev 14: 1293–1307.
13. Busby SA, Kumar N, Kuruvilla DS, Istrate MA, Conkright JJ, et al. (2011)
Identification of a novel non-retinoid pan inverse agonist of the retinoic acid
receptors. ACS Chem Biol 6: 618–627. 10.1021/cb100396s [doi].
14. Kumar N, Solt LA, Conkright JJ, Wang Y, Istrate MA, et al. (2010) The
benzenesulfoamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-
hydroxy-1-(trifluoromethyl)ethy l]phenyl]-benzenesulfonamide] is a novel re-
tinoic acid receptor-related orphan receptor-alpha/gamma inverse agonist. Mol
Pharmacol 77: 228–236. mol.109.060905 [pii];10.1124/mol.109.060905 [doi].
15. Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, et al. (2012) Regulation of
circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature
485: 62–68. nature11030 [pii];10.1038/nature11030 [doi].
16. Green H, Kehinde O (1975) An established preadipose cell line and its
differentiation in culture. II. Factors affecting the adipose conversion. Cell 5: 19–
27. 0092-8674(75)90087-2 [pii].
17. Richard AJ, Amini ZJ, Ribnicky DM, Stephens JM (2012) St. John’s Wort
inhibits insulin signaling in murine and human adipocytes. Biochim Biophys
Acta 1822: 557–563. S0925-4439(11)00283-3 [pii];10.1016/j.bba-
dis.2011.12.005 [doi].
18. Kuri-Harcuch W, Green H (1978) Adipose conversion of 3T3 cells depends on a
serum factor. Proc Natl Acad Sci U S A 75: 6107–6109.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985)
Homeostasis model assessment: insulin resistance and beta-cell function from
fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–
419.
Artemisia Induces Metabolically Favorable Effects in Fat
PLOS ONE | www.plosone.org 7 June 2014 | Volume 9 | Issue 6 | e98897
20. Frosig C, Jensen TE, Jeppesen J, Pehmoller C, Treebak JT, et al. (2013) AMPK
and insulin action – responses to ageing and high fat diet. PLoS One 8: e62338.
10.1371/journal.pone.0062338 [doi];PONE-D-12-39704 [pii].
21. Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, et al. (2003) Regulation
of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro
investigations in humans. Am J Physiol Endocrinol Metab 285: E527–E533.
10.1152/ajpendo.00110.2003 [doi];00110.2003 [pii].
22. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of
tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.
Science 259: 87–91.
23. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM (1995)
Increased adipose tissue expression of tumor necrosis factor-alpha in human
obesity and insulin resistance. J Clin Invest 95: 2409–2415. 10.1172/JCI117936
[doi].
24. Sartipy P, Loskutoff DJ (2003) Monocyte chemoattractant protein 1 in obesity
and insulin resistance. Proc Natl Acad Sci U S A 100: 7265–7270. 10.1073/
pnas.1133870100 [doi];1133870100 [pii].
25. Ruderman NB, Carling D, Prentki M, Cacicedo JM (2013) AMPK, insulin
resistance, and the metabolic syndrome. J Clin Invest 123: 2764–2772. 67227
[pii];10.1172/JCI67227 [doi].
26. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, et al. (2002) Adiponectin
stimulates glucose utilization and fatty-acid oxidation by activating AMP-
activated protein kinase. Nat Med 8: 1288–1295. 10.1038/nm788 [doi];nm788
[pii].
27. Brazil DP, Hemmings BA (2001) Ten years of protein kinase B signalling: a hard
Akt to follow. Trends Biochem Sci 26: 657–664. S0968-0004(01)01958-2 [pii].
28. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, et al. (1999) PPAR gamma
is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell
4: 611–617. S1097-2765(00)80211-7 [pii].
29. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, et al. (2011)
Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med
364: 1104–1115. 10.1056/NEJMoa1010949 [doi].
30. Tripathy D, Daniele G, Fiorentino TV, Perez-Cadena Z, Chavez-Velasquez A,
et al. (2013) Pioglitazone improves glucose metabolism and modulates skeletal
muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-
blind, placebo-controlled, mechanistic study. Diabetologia 56: 2153–2163.
10.1007/s00125-013-2976-z [doi].
31. Huang JV, Greyson CR, Schwartz GG (2012) PPAR-gamma as a therapeutic
target in cardiovascular disease: evidence and uncertainty. J Lipid Res 53: 1738–
1754. jlr.R024505 [pii];10.1194/jlr.R024505 [doi].
32. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial
infarction and death from cardiovascular causes. N Engl J Med 356: 2457–2471.
NEJMoa072761 [pii];10.1056/NEJMoa072761 [doi].
33. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B (2007) Safety issues
and prospects for future generations of PPAR modulators. Biochim Biophys
Acta 1771: 1065–1081. S1388-1981(07)00035-2 [pii];10.1016/j.bba-
lip.2007.02.003 [doi].
34. Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, et al. (2011)
Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-
mediated phosphorylation. Nature 477: 477–481. nature10383 [pii];10.1038/
nature10383 [doi].
35. Choi JH, Banks AS, Estall JL, Kajimura S, Bostrom P, et al. (2010) Anti-diabetic
drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature
466: 451–456. nature09291 [pii];10.1038/nature09291 [doi].
36. Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease.
Nat Rev Immunol 11: 98–107. nri2925 [pii];10.1038/nri2925 [doi].
37. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB (2006)
Adiponectin – a key adipokine in the metabolic syndrome. Diabetes Obes Metab
8: 264–280. DOM510 [pii];10.1111/j.1463-1326.2005.00510.x [doi].
38. Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, et al. (2003)
Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-
L1 adipocytes. Biochem Biophys Res Commun 301: 1045–1050.
S0006291X03000901 [pii].
39. Rotter V, Nagaev I, Smith U (2003) Interleukin-6 (IL-6) induces insulin
resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-
alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol
Chem 278: 45777–45784. 10.1074/jbc.M301977200 [doi];M301977200 [pii].
40. Bijland S, Mancini SJ, Salt IP (2013) Role of AMP-activated protein kinase in
adipose tissue metabolism and inflammation. Clin Sci (Lond) 124: 491–507.
CS20120536 [pii];10.1042/CS20120536 [doi].
41. Chopra I, Li HF, Wang H, Webster KA (2012) Phosphorylation of the insulin
receptor by AMP-activated protein kinase (AMPK) promotes ligand-indepen-
dent activation of the insulin signalling pathway in rodent muscle. Diabetologia
55: 783–794. 10.1007/s00125-011-2407-y [doi].
42. Shibata T, Takaguri A, Ichihara K, Satoh K (2013) Inhibition of the TNF-
alpha-induced serine phosphorylation of IRS-1 at 636/639 by AICAR. J
Pharmacol Sci 122: 93–102. DN/JST.JSTAGE/jphs/12270FP [pii].
43. Daval M, Foufelle F, Ferre P (2006) Functions of AMP-activated protein kinase
in adipose tissue. J Physiol 574: 55–62. jphysiol.2006.111484 [pii];10.1113/
jphysiol.2006.111484 [doi].
44. Obanda DN, Hernandez A, Ribnicky D, Yu Y, Zhang XH, et al. (2012)
Bioactives of Artemisia dracunculus L. mitigate the role of ceramides in
attenuating insulin signaling in rat skeletal muscle cells. Diabetes 61: 597–605.
db11-0396 [pii];10.2337/db11-0396 [doi].
45. Wang ZQ, Ribnicky D, Zhang XH, Raskin I, Yu Y, et al. (2008) Bioactives of
Artemisia dracunculus L enhance cellular insulin signaling in primary human
skeletal muscle culture. Metabolism 57: S58–S64. S0026-0495(08)00100-5
[pii];10.1016/j.metabol.2008.04.003 [doi].
46. Wang ZQ, Ribnicky D, Zhang XH, Zuberi A, Raskin I, et al. (2011) An extract
of Artemisia dracunculus L. enhances insulin receptor signaling and modulates
gene expression in skeletal muscle in KK-A(y) mice. J Nutr Biochem 22: 71–78.
S0955-2863(10)00009-4 [pii];10.1016/j.jnutbio.2009.11.015 [doi].
47. Wang ZQ, Zhang XH, Yu Y, Tipton RC, Raskin I, et al. (2013) Artemisia
scoparia extract attenuates non-alcoholic fatty liver disease in diet-induced
obesity mice by enhancing hepatic insulin and AMPK signaling independently of
FGF21 pathway. Metabolism 62: 1239–1249. S0026-0495(13)00084-X
[pii];10.1016/j.metabol.2013.03.004 [doi].
Artemisia Induces Metabolically Favorable Effects in Fat
PLOS ONE | www.plosone.org 8 June 2014 | Volume 9 | Issue 6 | e98897
